The list for the next round of medicines that will ... reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

The Blujepa nod is the second that GSK can check off its list of the five expected approvals it aims to pick up this year. Next up are hopeful expansions for its antibody-drug conjugate Blenrep ...

Significant delays in core FDA functions — such as approving amendments to clinical trials and guiding companies through ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

GSK was able to persuade NICE to change its mind after it provided further analyses on its use, as well as an additional price reduction. The drug’s list price is £840 per dose, but the price ...

Environmental contributors to autism are behind its rising prevalence, U.S. Health Secretary Robert F. Kennedy Jr. said on ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other most ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Forget whisky, cars or chemicals. The real blow to the British economy from President Trump’s determination to impose steep ...

Donald Trump has vowed to hit imports of pharmaceuticals with new tariffs in a major setback for one of Britain’s largest ...

Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to ...